Author

Yixuan Jacob Hou

Moderna Therapeutics (United States)ORCID 0000-0002-8323-7243Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Amy Gorrie· 2 shared Andrea Carfı́iD· 2 shared Arshan NasiriD· 2 shared Daniela Montes Berrueta· 2 shared Darin K. EdwardsiD· 2 shared Diana Wing LeeiD· 2 shared Hardik JaniiD· 2 shared Kath Hardcastle· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Amy Gorrie

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

mRNA-1273.251 and mRNA-1283.251 vaccines expressing SARS-CoV-2 variant LP.8.1 antigens broadly neutralize contemporary JN.1-lineage viruses

Arshan Nasir, Diana Wing Lee, Ziqiu Wang, Clinton O. Ogega, Nathen E. Bopp, Phylicia Wisti, Daniel L. Makrinos, Hardik Jani, Amy Gorrie, Michael F. Bender, Adrian R. Laciak, Arvind Sharma, Xiaozhen Hu, Tessa Speidel, Fadi Ghantous, , Alec W. Freyn

This study develops and evaluates two mRNA vaccines targeting the LP.8.1 variant of SARS-CoV-2, showing broad neutralization against JN.1-lineage subvariants.

bioRxiv · Sep 16, 2025 · PreprintImmunology

mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice

Diana Wing Lee, Arshan Nasir, Sayda M. Elbashir, Hardik Jani, Tessa Speidel, Amy Gorrie, Daniela Montes Berrueta, Philippa Martin, Swan Tan, Yixuan Jacob Hou, Kath Hardcastle, Darin K. Edwards, Kai Wu, Andrea Carfı́, Yadunanda Budigi

This study evaluates JN.1 and KP.2 mRNA vaccines in mice, showing they elicit strong neutralizing antibodies against JN.1 subvariants and cross-neutralize KP.3, LA.2, and XEC.

Vaccine · Mar 7, 2025Peer-reviewedImmunology